Samsung is reportedly gearing up to join a fresh $100 million funding round for Exo, a California-based medical imaging startup transforming handheld ultrasound with AI and silicon innovation. According to Bloomberg, Samsung’s venture arm could participate in the round led by Sands Capital, Bold Capital, and Qubit Health Capital.
Exo’s momentum continues to grow as it redefines how clinicians perform and share ultrasound exams. Its flagship product, a portable ultrasound device, plugs directly into a smartphone—letting healthcare professionals scan patients, record diagnostics, and instantly share reports within one streamlined app.
Founded in 2015, Exo blends artificial intelligence, silicon-based innovation, and advanced medical imaging into a single compact device. Designed to simplify procedures like lung scans and echocardiograms, Exo’s tool aims to boost both accessibility and efficiency in diagnostics—especially in emergency and resource-limited settings.
To date, the company has secured over $320 million in funding from top-tier investors such as BlackRock, Intel, Sony, RA Capital, Sands Capital, and Avidity Partners. Its most recent raise, a $220 million Series C in 2021, highlighted growing confidence in the startup’s mission to democratize high-quality imaging.
Adding further weight to the round, Qubit Health Capital’s chairman, Omar Ishrak—former CEO of Medtronic—is expected to join Exo’s board, deepening the company’s leadership experience in medtech innovation.
In addition to the investment, Exo is also exploring a strategic partnership with Samsung Medison, a subsidiary of Samsung specializing in ultrasound diagnostics and digital X-ray systems. A collaboration between the two could accelerate product development and market expansion, especially in global healthcare markets.
While neither Exo nor any of the involved firms have publicly commented on the funding, this potential investment signals strong interest in the convergence of AI and portable health diagnostics.
